Summary of Progyny Inc. (PGNY) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Achieved record quarterly revenue of approximately $335 million to $345 million, reflecting a 5.3% increase year-over-year (11% excluding a former client's transition agreement).

Gross Profit: Expanded gross margin by 180 basis points year-over-year.

Adjusted EBITDA: Reported adjusted EBITDA of $56 million to $59 million for Q3, with a trailing 12-month adjusted EBITDA margin of 17.2%.

Cash Flow: Generated over $50 million in operating cash flow for the fourth time in five quarters, totaling $201 million on a trailing 12-month basis.

Share Repurchases: Completed $31.5 million in share buybacks during the quarter, with a total of 2 million shares repurchased under the current program.

2Strategic Updates and Business Highlights

Sales Momentum: Strong early commitments for new sales, with expectations to add over 1 million new lives in 2026, driven by high client retention and diverse industry representation.

Market Position: Progyny's solutions are gaining traction as employers prioritize family building and women's health, particularly in light of rising healthcare costs.

Product Expansion: Continued development of Progyny Select, a fully insured market offering, with expectations for significant contributions in the medium to long term.

Client Retention: Successfully reduced retention risk earlier than usual, with existing clients showing strong commitment to maintaining and expanding their benefits.

3Forward Guidance and Outlook

2026 Revenue Guidance: Projected revenue between $1.36 billion to $1.385 billion, indicating growth of 5.5% to 7.5%.

Adjusted EBITDA Guidance: Expected between $233 million to $240 million for the year, with net income projected at $104.8 million to $109.9 million.

Q3 Guidance: Anticipated revenue of $335 million to $345 million, reflecting seasonal impacts but maintaining overall growth expectations.

4Bad News, Challenges, or Points of Concern

Seasonality Impact: Notable seasonal softness in member engagement during the summer, leading to a recalibration of guidance. Management does not view this as a long-term trend but acknowledges it as a current challenge.

Competitive Pressures: Increased interest from employers currently using competitor solutions, although specific dissatisfaction details remain anecdotal.

Market Conditions: Potential headwinds from broader employment trends and economic conditions affecting client decisions and engagement levels.

5Notable Q&A Insights

Seasonality Discussion: Management confirmed that the summer slowdown is typical and expected to normalize in September, with no significant long-term trend changes anticipated.

Client Engagement: Insights into the engagement from prospects indicate a mix of first-time fertility benefit seekers and those exploring alternatives to existing providers.

Future Investments: Management expressed confidence in their ability to balance investments in growth with shareholder returns, indicating a tapering of capital expenditures in the coming years.

International Expansion: While not a major revenue driver currently, Progyny is focusing on multinational companies to leverage their solutions globally. This summary encapsulates the key points from Progyny's Q2 2026 earnings call, highlighting both the positive developments and the challenges faced by the company.